期刊文献+

Preclinical characterization and anti-SARS-CoV-2 efficacy of ATV014:an oral cyclohexanecarboxylate prodrug of 1′-CN-4-aza-7,9-dideazaadenosine C-nucleoside

原文传递
导出
摘要 Dear Editor,Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),the causative agent of the global pandemic coronavirus disease 2019(COVID-19),has proven itself to be a highly virulent respiratory pathogen with an unpredictable evolutionary capacity,posing a persistent threat to mankind.At the time of this manuscript’s publication.
出处 《Signal Transduction and Targeted Therapy》 SCIE CSCD 2023年第2期355-357,共3页 信号转导与靶向治疗(英文)
基金 This work was supported by Shenzhen Science and Technology Program(JSGG20200225150431472,JSGG20210901145403012&KQTD20180411143323605) Guangdong Basic and Applied Basic Research Foundation(Grant#2020A1515110361) National Key Research and Development Program of China(#2021YFC0865100) Key-Area Research and Development Program of Guangdong Province(2021B1111110001) National Natural Science Foundation of China(grant#32041002,#82150206) D.G.is also supported by Guangdong Zhujiang Talents Program(#2016LJ06Y540)and National Ten-thousand Talents Program.The authors thank Lu Zhang,Ruyan Liao,Yongxia Shi and Jun Dai from Guangzhou Customs District Technology Center for the help in in vivo efficacy experiment.We also thank the other project participants,including Guanguan Li,Shuo Li and Xinjun Liu from Medi-X Pingshan,Southern University of Science and Technology for the support in preclinical study.
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部